Supplementary Materials

Supplementary Material for:

Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer

Isaac Garcia-Murillas, Gaia Schiavon, Britta Weigelt, Charlotte Ng, Sarah Hrebien, Rosalind J. Cutts, Maggie Cheang, Peter Osin, Ashutosh Nerurkar, Iwanka Kozarewa, Javier Armisen Garrido, Mitch Dowsett, Jorge S. Reis-Filho, Ian E. Smith, Nicholas C. Turner*

*Corresponding author. E-mail: nicholas.turner{at}icr.ac.uk

Published 26 August 2015, Sci. Transl. Med. 7, 302ra133 (2015)
DOI: 10.1126/scitranslmed.aab0021

This PDF file includes:

  • Fig. S1. Mutation tracking by dPCR along a 24-month follow-up of a disease-free patient.
  • Fig. S2. High-depth targeted capture MPS on plasma DNA from two relapsed patients.
  • Fig. S3. Copy number profile in primary tumor and plasma DNA before relapse.
  • Fig. S4. Validation and follow-up of MPS on plasma DNA.
  • Fig. S5. CONSORT flow diagram of patients included in this study.
  • Table S1. dPCR assays and mutations analyzed in this study.
  • Table S2. Clinicopathological factors associated with baseline ctDNA level.
  • Table S3. Prediction of disease-free survival using a single postsurgical blood sample.
  • Table S4. Prediction of disease-free survival by mutation tracking using serial blood samples.
  • Table S5. Summary of the study cohort.
  • Table S6. Ion AmpliSeq breast cancer driver gene panel.
  • Table S7. Reads from capture MPS of tumor and plasma DNA.

[Download PDF]